

School of Medicine – São Paulo University (USP)

Av. Dr. Arnaldo, 455, Cerqueira César

Pacaembu – SP

CEP: 01246-903

November 12, 2021

Dear Editor and Reviewers,

Thank you for your valuable comments. Below are the answers:

1. It should be a case report instead of a letter to editor. So, this manuscript should be re-submitted as a case report.

-Answer: We thank the reviewer's consideration. We preferred to submit it as a "Letter to Editor" to share briefly our experience of rituximab in a refractory case with HIV-associated nemaline myopathy.

2. Nemaline myopathy isn't included in the list of indications of rituximab. Did the authors get the approval of both the patients and the ethics committee ? If yes, the documentary evidences must be provided.

-Answer: According to the literature, nemaline myopathy-HIV usually has a good response to immunosuppressive therapy. However, our patient had refractory to glucocorticoid, and conventional immunosuppressives; therefore, despite off-label, and after patient consent, we introduced the rituximab as a possible option to promote disease induction.

3. The long-term prognosis of this treatment should be provided. So, major revision should be recommended for this manuscript."

-Answer: We added long-term prognosis in the present case.

Regards